2007 NSTI Nanotechnology Conference and Trade Show - Nanotech 2007 - 10th Annual

Targeted Aptamer-Nanoparticles to Diminish Drug Resistance of Cancer Cells in vitro Study

P. Basto, F. Alexis, E. Levy-Nissenbaum, R. Langer and O. Farokzhad
Massachusetts Institute of Technology, US

docetaxel, prostate cancer, targeted delivery, poly (D, L-lactic-co-glycolic acid) (PLGA)

Using prostate cancer as a model, we report the drug release of pacitaxel and doxorubicin from aptamer-poly (D,L lactic co glycolic acid)-poly(ethylene glycol) (PLGA-PEG) nanoparticles used to target prostate-specific membrane antigen (PSMA), a well characterized antigen that is expressed on the surface of prostate cancer cells. Doxorubicin functions as an inhibitor of topoisomoerase II progression to halt replication. Pacitaxel stops the formation of mitotic spindles which interrupts cell division. In our study, the doxorubicin non-covalently intercalated in the aptamer on the surface of the nanoparticles and the pacitaxel is encapsulated within the bulk polymer unit for a powerful delivery method of both drugs at different release rates acting synergistically. In vitro toxicity assays have shown the targeting efficiency of these nanoparticles and the synergistic effect of the two drugs are higher than a single drug delivery system. These targeted drug delivery nanoparticles could be used as a powerful therapeutic tool, in comparison to the single drug approach, to combat cancer cells displaying drug resistance.

Back to Program

Sessions Sunday Monday Tuesday Wednesday Thursday Authors Keywords

Nanotech 2007 Conference Program Abstract


Names, and logos of other organizations are the property of those organizations and not of NSTI.
This event is not open to the general public and NSTI reserves the right to refuse admission and participation to any individual.